tbuckley/cabot-search huggingface dataset:
Abstract 171: A Mitral Regurgitation May be an Early Diagnostic Clue to Kawasaki Disease in Young Infants with Atypical Presentations
Authors: Jin-Hee Oh, Ji Hoon Kim, Ji Eun Lee, Hyo Jin Kwon, Jae Young Lee, Soon Ju Lee, Ji Whan Han, Kyung Yil Lee, Dae Kyun Koh
Journal: Circulation (2015)

Background: Very young infants with Kawasaki disease (KD) often present with atypical features that render diagnosis difficult and the incidence of coronary complications high. Picking up clues at early phase of KD can be critical. Herein we present 3 cases of KD in very young infants who showed mitral regurgitation (MR) around the 7th day from the onset of fever. They received IVIG around 7th fever day. However, the advice for short-term follow up echocardiography (ECHO) was neglected as clinical course thereafter were so unusual. Giant coronary aneurysms developed in all the patients later. Case 1: A 31-day-old infant got admission care for sepsis. ECHO at the 7th day from the onset of fever showed trivial MR and the patient received IVIG. Follow up ECHO was recommended, but was not conducted as clinical course was ambiguous for KD thereafter. Being treated with steroids due to skin rash and eosinophilia that masked patient’s fever, the infant reappeared to hospital with cardiogenic shock 10 days later. ECHO revealed giant aneurysms in the right coronary artery (RCA) and CT angiography for pulsating axillary masses revealed axillary aneurysms. Case 2; A 67-day-old infant was admitted with fever and persistent thrombodytopenia. ECHO done at the 5th day from the onset of fever due to red lips showed non-specific findings. Follow up ECHO at the 7th fever day showed newly developed MR. IVIG and steroids was added on for persistent fever, but severe leukocytosis ensued and clinical course was also ambiguous for KD. Defervescence was achieved with infliximab. The infant showed coronary aneurysms. Case 3; A 80-day-old infant was admitted with fever and seizure, and treated for sepsis. On the 6th day from the onset of fever, MR was shown on ECHO and the patient received IVIG and steroids. However, fever and severe anemia, left shift of leukocytes, and severe thrombocytopenia persisted for two weeks. Giant coronary aneurysms, as large as the ascending aorta, developed in the RCA. Pulsatile masses identified in the axilla were found to be large aneurysms on CT angiography. Conclusion: A newly developed MR, even trivial, around the 7th day from the onset of fever may be a clue to the diagnosis of KD and short term follow up ECHO is recommended for ongoing febrile infants younger than 3 months.
Patient monitoring of changes in the European policy response to viral hepatitis C treatment: Hep-CORE findings from 2016 to 2017
Authors: J. Lazarus, S.R. Stumo, C. Gore, M. Harris, G. Hendrickx, M. Jauffret-Roustide, A. Kautz, M. Maticic, T. Reic, K. Safreed-Harmon
Journal: Journal of Hepatology (2018)
Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk for Screen-Detected and Interval Cancers
Authors: Karla Kerlikowske, Christopher G. Scott, Amir P. Mahmoudzadeh, Lin Ma, Stacey Winham, Matthew R. Jensen, Fang Fang Wu, Serghei Malkov, V. Shane Pankratz, Steven R. Cummings, John A. Shepherd, Kathleen R. Brandt, Diana L. Miglioretti, Celine M. Vachon
Journal: Annals of Internal Medicine (2018)

Background: In 30 states, women who have had screening mammography are informed of their breast density on the basis of Breast Imaging Reporting and Data System (BI-RADS) density categories estimated subjectively by radiologists. Variation in these clinical categories across and within radiologists has led to discussion about whether automated BI-RADS density should be reported instead. Objective: To determine whether breast cancer risk and detection are similar for automated and clinical BI-RADS density measures. Design: Case–control. Setting: San Francisco Mammography Registry and Mayo Clinic. Participants: 1609 women with screen-detected cancer, 351 women with interval invasive cancer, and 4409 matched control participants. Measurements: Automated and clinical BI-RADS density assessed on digital mammography at 2 time points from September 2006 to October 2014, interval and screen-detected breast cancer risk, and mammography sensitivity. Results: Of women whose breast density was categorized by automated BI-RADS more than 6 months to 5 years before diagnosis, those with extremely dense breasts had a 5.65-fold higher interval cancer risk (95% CI, 3.33 to 9.60) and a 1.43-fold higher screen-detected risk (CI, 1.14 to 1.79) than those with scattered fibroglandular densities. Associations of interval and screen-detected cancer with clinical BI-RADS density were similar to those with automated BI-RADS density, regardless of whether density was measured more than 6 months to less than 2 years or 2 to 5 years before diagnosis. Automated and clinical BI-RADS density measures had similar discriminatory accuracy, which was higher for interval than screen-detected cancer (c-statistics: 0.70 vs. 0.62 [P < 0.001] and 0.72 vs. 0.62 [P < 0.001], respectively). Mammography sensitivity was similar for automated and clinical BI-RADS categories: fatty, 93% versus 92%; scattered fibroglandular densities, 90% versus 90%; heterogeneously dense, 82% versus 78%; and extremely dense, 63% versus 64%, respectively. Limitation: Neither automated nor clinical BI-RADS density was assessed on tomosynthesis, an emerging breast screening method. Conclusion: Automated and clinical BI-RADS density similarly predict interval and screen-detected cancer risk, suggesting that either measure may be used to inform women of their breast density. Primary Funding Source: National Cancer Institute.
Improving the Propranolol Treatment of Melanoma
Authors: Salvatore Patanè
Journal: JAMA Oncology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Locum GP who gave poor care to five patients is struck off
Authors: Clare Dyer
Journal: BMJ (2018)

An out of hours locum GP who gave substandard care to five patients and made dishonest statements on a cremation form has been struck off by a medical practitioners’ tribunal panel in Manchester.

Vikram Krishnappa was found to have provided poor clinical care to five patients over a 14 month period between late 2013 and early 2015, while working as a locum GP in the out of hours service at Cardiff Royal Infirmary.

Most of the cases involved multiple failings and each, on its own, constituted serious misconduct, the tribunal ruled.

In the case of a 3 week old baby, he failed to urgently …
Double-tunnel method for treatment of colorectal lesions with severe fibrosis with endoscopic submucosal dissection
Authors: Hideyuki Chiba, Ken Ohata, Maiko Takita, Jun Tachikawa, Keiichi Ashikari, Toru Goto, Atsushi Nakajima
Journal: Endoscopy (2018)

Endoscopic submucosal dissection (ESD) for gastrointestinal lesions enables en bloc resection with tumor-free margins and is not limited by the lesion size or location. However, en bloc removal of colorectal lesions with severe fibrosis is difficult and requires a longer time [1] [2]. We report the successful resection of an early rectal tumor by colorectal ESD with a new method: double-tunnel ESD.
Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC).
Authors: Pedro C. Barata, Dharmesh Gopalakrishnan, Paul Elson, Vadim S. Koshkin, Moshe Chaim Ornstein, C. Marcela Diaz-Montero, Samuel Haywood, Patricia A. Rayman, James Finke, Marcelo Lamenza, Sarah Devonshire, Pam Profusek, Kimberly D Allman, Allison Martin, Jennifer Beach, Kim Schach, Timothy D. Gilligan, Brian I. Rini, Jorge A. Garcia, Petros Grivas
Journal: Journal of Clinical Oncology (2017)

e16031 Background: Atezo was recently FDA-approved for patients (pts) with UC (IMvigor210 trial). We assessed the safety and efficacy of Atezo in the real world setting and explored the role of putative biomarkers. Methods: Data from 44 consecutive non-trial pts with UC treated with ≥1 dose of Atezo 1200mg IV q3w at Cleveland Clinic (May - Dec 2016) were available. Demographic, clinicopathologic, biomarker data, including blood neutrophil to lymphocyte ratio (NLR) and myeloid derived suppressor cell (MDSC) populations [LinloCD33+/HLADR-(Total), and Granulocytic(CD15+CD14-), Monocytic(CD15-CD14+), Immature(CD15-CD14-), CD11b+ subsets], were collected. Response, progression-free survival (PFS) and overall survival (OS) were measured (RECIST v1.1). Adverse events (AE) were reported (CTCAE v4.03). Outcome data were analyzed with Fisher’s exact test, chi-square tests, log rank test and proportional hazards models. Results: Median age was 68y (34-88), 68% men, 68% pure urothelial histology, 27% never smokers; 61% PS &gt; 0, 61% visceral metastases, 57% CrCl &lt; 60 mL/min, 84% bladder primary, 61% prior cystectomy. In metastatic setting, 25% had ≥2 prior systemic therapies, 84% prior platinum-based regimen, and 9% no prior therapy. With median follow-up of 3.3 months ( &lt; 1 - 6.6) and median number of 3 doses, in 38 pts evaluable for response, 21% had PR; 24% SD; 61% progressed, 27% died; estimated median (m)PFS was 3 months (95%CI 2.2 - 4.3) and mOS was 5.2 months (95%CI 4.6 - NR). Only 3/27 eligible pts got subsequent treatment. Number of metastatic sites, 2 Bellmunt prognostic factors, and NLR ≥ 5.0 negatively impacted response, PFS and OS. MDSC populations (data available in 14 pts) demonstrated non-significant correlation with worse outcome and elevated NLR. Most frequent all-cause AE ( &gt; 20%) were fatigue (60%, G3:9%), anorexia (33%, G3:7%), elevated creatinine (26%, G3:5%); 1 pt had G4 hyperbilirubinemia. There were no treatment-related deaths. Conclusions: To our knowledge, this is the largest real-world experience with Atezo in UC. Response and toxicity were comparable to IMvigor210 trial; estimated mOS was shorter but with limited follow up. Higher NLR had negative prognostic value, while the role of MDSCs merits further exploration.
VIEKIRA PAK (ritonavir-boosted paritavir/ombitasvir and dasabuvir) associated drug-induced interstitial lung disease: Case series with systematic review
Authors: Y.J. Wong, S.Y. Chew, P.H. Thurairajah, R. Kumar, J.H. Chen, R.S. Gokhle, I.M. Noor, J. Tan
Journal: Journal of Hepatology (2018)
National quality control and validation of hepatitis C NS3, NS5A and NS5B genotypic resistance testing
Authors: T. Ruggiero, V. Cento, M. Aragri, M. Arosio, F. Baldanti, M. Brunetto, B. Bruzzone, E. Boeri, D. Cavallone, C. Nicola, M.A.D. Stefano, V. Ghisetti, M.P. Callegaro, M.R. Capobianchi, C. Caudai, N. Cuomo, S. Galli, E. Galmozzi, A. Garbuglia, W. Gennari, A. Lai, S. Menzo, V. Micheli, C. Minosse, L. Monno, S. Paolucci, T. Pollicino, A. Raddi, G. Raffa, G. Raimondo, M. Sanguinetti, R. Santangelo, T. Santantonio, S. Soldini, M. Starace, M.L. Vatteroni, A. Craxi, C.F. Perno, F.C. Silberstein, M. Zazzi
Journal: Journal of Hepatology (2018)
P78Electrophysiological characterization of induced pluripotent stem cell-derived cardiomyocytes from duchenne muscular dystrophy patients
Authors: J M Pioner, R Coppini, L Santini, C Palandri, E Bennati, M Regnier, L Sacconi, E Cerbai, C Poggesi, C Ferrantini
Journal: Cardiovascular Research (2018)
Has increased rollout of DAA therapy decreased the burden of late presentation and advanced liver disease in patients starting HCV therapy in Germany?
Authors: J. Rockstroh, C. Boesecke, P. Ingiliz, B. Florian, K.-G. Simon, L. Thomas, K. Schewe, J. Schulze, Z. Wiesch, D. Hüppe, S. Christensen, S. Mauss
Journal: Journal of Hepatology (2018)
Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma
Authors: Pravin Kesarwani, Antony Prabhu, Shiva Kant, Praveen Kumar, Stewart F. Graham, Katie L. Buelow, George D. Wilson, C. Ryan Miller, Prakash Chinnaiyan
Journal: Clinical Cancer Research (2018)

Abstract Purpose: Immune checkpoint inhibitors designed to revert tumor-induced immunosuppression have emerged as potent anticancer therapies. Tryptophan metabolism represents an immune checkpoint, and targeting this pathway's rate-limiting enzyme IDO1 is actively being investigated clinically. Here, we studied the intermediary metabolism of tryptophan metabolism in glioblastoma and evaluated the activity of the IDO1 inhibitor GDC-0919, both alone and in combination with radiation (RT). Experimental Design: LC/GC-MS and expression profiling was performed for metabolomic and genomic analyses of patient-derived glioma. Immunocompetent mice were injected orthotopically with genetically engineered murine glioma cells and treated with GDC-0919 alone or combined with RT. Flow cytometry was performed on isolated tumors to determine immune consequences of individual treatments. Results: Integrated cross-platform analyses coupling global metabolomic and gene expression profiling identified aberrant tryptophan metabolism as a metabolic node specific to the mesenchymal and classical subtypes of glioblastoma. GDC-0919 demonstrated potent inhibition of this node and effectively crossed the blood–brain barrier. Although GDC-0919 as a single agent did not demonstrate antitumor activity, it had a strong potential for enhancing RT response in glioblastoma, which was further augmented with a hypofractionated regimen. RT response in glioblastoma involves immune stimulation, reflected by increases in activated and cytotoxic T cells, which was balanced by immune checkpoint reactivation, reflected by an increase in IDO1 expression and regulatory T cells (Treg). GDC-0919 mitigated RT-induced Tregs and enhanced T-cell activation. Conclusions: Tryptophan metabolism represents a metabolic node in glioblastoma, and combining RT with IDO1 inhibition enhances therapeutic response by mitigating RT-induced immunosuppression. Clin Cancer Res; 24(15); 3632–43. ©2018 AACR.
Increased FDG Uptake in a Giant Bone Island Mimicking Malignancy
Authors: Pengcheng Ran, Aisheng Dong, Yang Wang, Yu Zhang, Shanshan Wu
Journal: Clinical Nuclear Medicine (2018)

Abstract Histologically proven bone islands exhibiting increased FDG uptake have been rarely reported before. We present a case with active giant bone island in the left humerus showing increased FDG uptake with SUVmax of 3.8. The diagnosis was confirmed by open biopsy and follow-up. Increased osteoblastic activity, proliferating and active fibroblasts, and increased blood flow may contribute to the increased FDG uptake of this giant bone island. This case indicates bone island should be included in the differential diagnosis of abnormal FDG uptake in focal sclerotic bone lesions, especially in patients with known malignancy.
<i>Notes from the Field:</i>Diarrhea and Acute Respiratory Infection, Oral Cholera Vaccination Coverage, and Care-Seeking Behaviors of Rohingya Refugees — Cox’s Bazar, Bangladesh, October–November 2017
Authors: Aimee Summers, Alexa Humphreys, Eva Leidman, Leonie Toroitich Van Mil, Caroline Wilkinson, Anuradhha Narayan, Mohammad Lalan Miah, Blanche Greene Cramer, Oleg Bilukha
Journal: MMWR Morbidity and Mortality Weekly Report (2018)
Association of Cannabis With Cognitive Functioning in Adolescents and Young Adults
Authors: J. Cobb Scott, Samantha T. Slomiak, Jason D. Jones, Adon F. G. Rosen, Tyler M. Moore, Ruben C. Gur
Journal: JAMA Psychiatry (2018)

<h3>Importance</h3> Substantial shifts in perception and policy regarding cannabis have recently occurred, with use of cannabis increasing while its perceived harm decreases. One possible risk of increased cannabis use is poorer cognitive functioning, especially in youth. <h3>Objective</h3> To provide the first quantitative synthesis of the literature examining cannabis and cognitive functioning in adolescents and young adults (with a mean age of 26 years and younger). <h3>Data Sources</h3> PubMed, PsycInfo, Academic Search Premier, Scopus, and bibliographies of relevant reviews were searched for peer-reviewed, English-language studies from the date the databases began through May 2017. <h3>Study Selection</h3> Consensus criteria were used to determine study inclusion through abstract and manuscript review. <h3>Data Extraction and Synthesis</h3> This study followed Meta-analysis of Observational Studies in Epidemiology guidelines. Effect size estimates were calculated using multivariate mixed-effects models for cognitive functioning outcomes classified into 10 domains. <h3>Main Outcomes and Measures</h3> Results from neurocognitive tests administered in cross-sectional studies were primary outcomes, and we examined the influence of a priori explanatory variables on variability in effect size. <h3>Results</h3> Sixty-nine studies of 2152 cannabis users (mean [SD] age, 20.6 [2.8] years; 1472 [68.4%] male) and 6575 comparison participants with minimal cannabis exposure were included (mean [SD] age, 20.8 [3.4]; 3669 [55.8%] male). Results indicated a small overall effect size (presented as mean<i>d</i>) for reduced cognitive functioning associated with frequent or heavy cannabis use (<i>d</i>, −0.25; 95% CI, −0.32 to −0.17;<i>P</i> &lt; .001). The magnitude of effect sizes did not vary by sample age or age at cannabis use onset. However, studies requiring an abstinence period longer than 72 hours (15 studies; n = 928) had an overall effect size (<i>d</i>, −0.08; 95% CI, −0.22 to 0.07) that was not significantly different from 0 and smaller than studies with less stringent abstinence criteria (54 studies; n = 7799;<i>d</i>, −0.30; 95% CI, −0.37 to −0.22;<i>P</i> = .01). <h3>Conclusions and Relevance</h3> Associations between cannabis use and cognitive functioning in cross-sectional studies of adolescents and young adults are small and may be of questionable clinical importance for most individuals. Furthermore, abstinence of longer than 72 hours diminishes cognitive deficits associated with cannabis use. Although other outcomes (eg, psychosis) were not examined in the included studies, results indicate that previous studies of cannabis in youth may have overstated the magnitude and persistence of cognitive deficits associated with use. Reported deficits may reflect residual effects from acute use or withdrawal. Future studies should examine individual differences in susceptibility to cannabis-associated cognitive dysfunction.
Efficacy and Safety of Subcutaneous Belimumab in Anti-Double-Stranded DNA-Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
Authors: A. Doria, W. Stohl, A. Schwarting, M. Okada, M. Scheinberg, R. van Vollenhoven, A. E. Hammer, J. Groark, D. Bass, N. L. Fox, D. Roth, D. Gordon
Journal: Arthritis & Rheumatology (2018)

To investigate the efficacy and safety of belimumab, a human immunoglobulin monoclonal antibody against B lymphocyte stimulator, in a subset of patients with systemic lupus erythematosus (SLE) who were hypocomplementemic (C3 <90 mg/dl and/or C4 <10 mg/dl) and anti-double-stranded DNA (anti-dsDNA) positive (≥30 IU/ml) at baseline.
TCTAP A-101 Comparison of Hydrophilic Polyethylene Glycol-coating Stent and Hydrophobic Octadecyl Thiol-coating Stent Implantation in Porcine Coronary Restenosis Model
Authors: Jeong Cheon Choe, Han Cheol Lee, Jinhee Ahn, Jin Sup Park, Hye Won Lee, Jun-Hyok Oh, Jung Hyun Choi, Kwang Soo Cha, Taek Jong Hong
Journal: Journal of the American College of Cardiology (2018)
PM20D1 is a quantitative trait locus associated with Alzheimer’s disease
Authors: Jose V. Sanchez-Mut, Holger Heyn, Bianca A. Silva, Lucie Dixsaut, Paula Garcia-Esparcia, Enrique Vidal, Sergi Sayols, Liliane Glauser, Ana Monteagudo-Sánchez, Jordi Perez-Tur, Isidre Ferrer, David Monk, Bernard Schneider, Manel Esteller, Johannes Gräff
Journal: Nature Medicine (2018)
Cumulative exposure to biological therapy and risk of cancer in patients with psoriasis: a meta-analysis of Psonet studies from Israel, Italy, Spain, the U.K. and Republic of Ireland
Authors: I. Garcia-Doval, M.A. Descalzo, K.J. Mason, A.D. Cohen, A.D. Ormerod, F.J. Gómez-García, S. Cazzaniga, I. Feldhamer, H. Ali, E. Herrera-Acosta, C.E.M. Griffiths, R.S. Stern, L. Naldi
Journal: British Journal of Dermatology (2018)

Cancer risk following long-term exposure to systemic immunomodulatory therapies in patients with psoriasis is possible.To assess a dose-response relationship between cumulative length of exposure to biological therapy and risk of cancer.Four national studies (a healthcare database from Israel, and prospective cohorts form Italy, Spain and the U.K. and Republic of Ireland) collaborating through Psonet (European Registry of Psoriasis) participated in these nested case-control studies, including nearly 60 000 person-years of observation. 'Cases' were patients who developed an incident cancer. Patients with previous cancers and benign or in situ tumours were excluded. Four cancer-free controls were matched to each case on year of birth, sex, geographic area and registration year. Follow-up for controls was censored at the date of cancer diagnosis for the matched case. Conditional logistic regression was performed by each registry. Results were pooled using random-effects meta-analysis.A total of 728 cases and 2671 controls were identified. After matching, differences between cases and controls were present for the Charlson Comorbidity Index in all three registries, and in the prevalence of previous exposure to psoralen-ultraviolet A and smoking (the British Association of Dermatologists Biologic Interventions Register only). The risk of first cancers was not significantly associated with cumulative exposure to biologics (adjusted odds ratio per year of exposure 1·02, 95% confidence interval 0·92-1·13). Results were similar if squamous and basal cell carcinomas were included in the outcome.Cumulative length of exposure to biological therapies in patients with psoriasis in real-world clinical practice does not appear to be linked to a higher risk of cancer after several years of use.
202Slow release of cardiac progenitor cell-derived extracellular vesicles from a pH-switchable hydrogel
Authors: E Mol, Z Lei, M H Bakker, P Vader, R M Schiffelers, PYW Dankers, SAJ Chamuleau, P A Doevendans, M J Goumans, J P Sluijter
Journal: Cardiovascular Research (2018)
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: a validation study of the HAP and SAP scores
Authors: F. Tovoli, G.G.D. Costanzo, G. Magini, F. Trevisani, T. Pressiani, R. Sacco, S. Marinelli, R. Tortora, L. Bucci, M.G. Lucà, L. Bolondi, A. Granito
Journal: Journal of Hepatology (2018)